PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice
Journal of Diabetes Investigation · 2024-11 · 15 (11) · 1566-1577
DOI: 10.1111/jdi.14291 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Diabetes Investigation, online erschienen am 22.08.2024. Verfasst von Daisuke Yabe und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemic Agents, Glycated Hemoglobin. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Novo Nordisk A/S.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aims/Introduction PIONEER REAL Japan was a non‐interventional prospective study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Materials and Methods Adults naïve to injectable glucose‐lowering therapies initiated oral semaglutide in routine clinical practice and were followed for 34–44 weeks. The primary endpoint was change in glycated hemoglobin (HbA 1c ) from baseline to end of study; the co‐primary endpoint was number of adverse events (AEs). Secondary endpoints included change in bodyweight from baseline to end of study. Analyses were also carried out for subgroups aged
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diabetes, Endocrinology and Nutrition, Kyoto University Graduate School of Medicine, Kyoto, Japan.
- Department of Diabetes, Endocrinology and Metabolism and Department of Rheumatology and Clinical Immunology, Gifu University Graduate School of Medicine, Gifu, Japan.
- Center for One Medicine Innovative Translational Research, Gifu University, Gifu, Japan.
- Yutaka Seino Distinguished Center for Diabetes Research, Kansai Electric Power Medical Research Institute, Kyoto, Japan.
- Center for Diabetes, Endocrinology and Metabolism, Kansai Electric Power Hospital, Osaka, Japan.
- Department of Endocrinology and Diabetes, Fukuoka University School of Medicine, Fukuoka, Japan.
ORCID-Profile: Daisuke Yabe, Yoshiyuki Hamamoto, Daiji Kawanami, Ryo Suzuki
Förderung
- Novo Nordisk A/S
Zitieren
APA
Yabe, D., Hamamoto, Y., Kawanami, D., Nishimura, R., Terauchi, Y., Amadid, H., Braae, U. C., Major-Pedersen, A., & Suzuki, R. (2024). PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Journal of Diabetes Investigation, 15(11), 1566-1577. https://doi.org/10.1111/jdi.14291
Vancouver
Yabe D, Hamamoto Y, Kawanami D, Nishimura R, Terauchi Y, Amadid H, et al. PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice. Journal of Diabetes Investigation. 2024;15(11):1566-1577. doi:10.1111/jdi.14291
BibTeX
@article{Yabe2024,
author = {Yabe, Daisuke and Hamamoto, Yoshiyuki and Kawanami, Daiji and Nishimura, Rimei and Terauchi, Yasuo and Amadid, Hanan and Braae, Uffe Christian and Major-Pedersen, Atheline and Suzuki, Ryo},
title = {PIONEER REAL Japan: Primary results from a multicenter, prospective, real‐world study of oral semaglutide in adults with type 2 diabetes in Japanese clinical practice},
journal = {Journal of Diabetes Investigation},
year = {2024},
volume = {15},
number = {11},
pages = {1566--1577},
doi = {10.1111/jdi.14291}
}
EUVIMED